Cartesian Therapeutics (RNAC) Cash from Investing Activities (2015 - 2026)
Cartesian Therapeutics' (RNAC) quarterly Cash from Investing Activities came in at -$27000.0 in Q1 2026, up 97.49% year-on-year from -$13671.7 in Q1 2025, and up 94.51% on a QoQ basis from -$492000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Cash from Investing Activities data on file, last reported at -$27000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 97.49% year-over-year to -$27000.0 in Q1 2026; TTM through Mar 2026 was -$4.4 million, a 52.19% increase from a year earlier, with the FY2025 full-year figure at -$5.5 million, up 37.61% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$27000.0, up from -$492000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for RNAC reached as high as $28.1 million in Q1 2023 and fell as low as -$29.9 million in Q3 2022.
- Historically, Cash from Investing Activities has averaged $336500.0 across 5 years, with a median of -$423000.0 in 2024.
- Across the five-year window, Cash from Investing Activities jumped 194.65% in 2023 and sank 13125.0% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at $5.5 million in 2022, then gained by 18.36% to $6.5 million in 2023, then slumped by 105.45% to -$354000.0 in 2024, then sank by 38.98% to -$492000.0 in 2025, then surged by 94.51% to -$27000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$27000.0 in Q1 2026, -$492000.0 in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Cartesian Therapeutics | 212.96 Mn | 212.96 Mn | - | -27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27,000.00 |
| Mar 31, 2026 | -27,000.00 |
| Dec 31, 2025 | -492,000.00 |
| Dec 31, 2025 | -492,000.00 |
| Sep 30, 2025 | -1.29 Mn |
| Sep 30, 2025 | -1.29 Mn |
| Jun 30, 2025 | -2.60 Mn |
| Jun 30, 2025 | -2.60 Mn |
| Mar 31, 2025 | -1.08 Mn |
| Mar 31, 2025 | -1.08 Mn |
| Dec 31, 2024 | -354,000.00 |
| Dec 31, 2024 | -354,000.00 |
| Sep 30, 2024 | -6.20 Mn |
| Sep 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Mar 31, 2024 | -602,000.00 |
| Mar 31, 2024 | -602,000.00 |
| Dec 31, 2023 | 6.50 Mn |
| Dec 31, 2023 | 6.50 Mn |